Understanding the Market | QYUNS-B opened over 6% higher after reaching a global exclusive licensing agreement for QX031N with Roche, with an upfront payment of USD 75 million
I'm PortAI, I can summarize articles.
QYUNS-B has reached a global exclusive licensing agreement with Roche, with an upfront payment of USD 75 million. The stock opened over 6% higher, rising 6.49% to HKD 26.9. The agreement involves the independently developed long-acting dual antibody QX031N, for which Roche will be responsible for research, development, registration, production, and commercialization. QX031N is expected to become a new therapy for diseases such as COPD and asthma. The founder of QYUNS-B stated that this collaboration will maximize the global value of the product
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments